HC Wainwright Has Optimistic View of TSE:MSL FY2030 Earnings

Merus Labs International Inc. (TSE:MSL) (NASDAQ:MSLI) – Stock analysts at HC Wainwright lifted their FY2030 earnings per share (EPS) estimates for shares of Merus Labs International in a research report issued to clients and investors on Monday, May 18th. HC Wainwright analyst A. He now forecasts that the specialty pharmaceutical company will post earnings of $0.48 per share for the year, up from their previous forecast of $0.47.

A number of other analysts also recently weighed in on the company. Guggenheim upgraded Merus Labs International to a “strong-buy” rating in a research report on Tuesday, April 28th. Cantor Fitzgerald upgraded Merus Labs International to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, Leerink Partners upgraded Merus Labs International to a “strong-buy” rating in a research report on Monday, April 6th. Three equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the stock currently has an average rating of “Strong Buy”.

Merus Labs International Price Performance

Merus Labs International has a one year low of C$0.95 and a one year high of C$1.76.

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.